Ivermectin

Ivermectin is an antiparasitic drug belonging to the avermectin class, a family of macrocyclic lactones produced by bacterial fermentation ^[1][2]. The commercial substance is a roughly 80 to 20 mixture of two closely related dihydroavermectin components, and it is prepared for both oral and topical use ^[1]. It is effective against a wide range of parasitic worms and external parasites while remaining comparatively safe for mammals at the doses used in treatment ^[2].

The compound traces back to a soil-dwelling bacterium, Streptomyces avermitilis, isolated in Japan in 1970 by Satoshi Omura, whose samples were studied at the pharmaceutical company Merck by William Campbell ^[1]. Their work identified the avermectins and led to ivermectin, a semi-synthetic derivative with improved properties ^[1]. Omura and Campbell shared half of the 2015 Nobel Prize in Physiology or Medicine for the discovery, which sharply reduced the burden of river blindness and lymphatic filariasis in affected regions ^[1].

In human medicine ivermectin is a treatment of choice for onchocerciasis, commonly called river blindness, and for strongyloidiasis, and it is also used for lymphatic filariasis, scabies, and infestations with lice ^[1][2]. A topical form is applied for the inflammatory skin condition rosacea, which is linked to Demodex mites ^[2]. In veterinary practice it is widely given to prevent heartworm in dogs and to control gastrointestinal and other parasites in livestock and companion animals ^[2].

Ivermectin was approved for human use in 1987 and appears on the World Health Organization's List of Essential Medicines ^[2]. It is a prescription medicine available as a generic, sold under brand names such as Stromectol and the topical Soolantra for people, and Heartgard and Mectizan in other settings ^[1][2].

During the COVID-19 pandemic, false claims spread that ivermectin could prevent or treat the disease; a Cochrane systematic review of randomized trials concluded that it offers no meaningful benefit for COVID-19, and major health agencies advised against such use ^[2][3]. The drug's overall safety record is regarded as excellent, though pharmacovigilance studies have catalogued rare serious reactions, including neurological events that can occur in people co-infected with the Loa loa parasite ^[3][4].

At approved antiparasitic doses it is generally well tolerated, with side effects like dizziness, nausea, and itching, sometimes from the immune reaction to dying parasites. High or repeated off-label doses, or veterinary formulations, can cause neurological toxicity, and overdoses have led to hospitalizations. It should only be used under medical guidance and never in animal-product form meant for livestock.

Ivermectin's interactions follow from two handling routes: CYP3A4 does most of its metabolism, and P-glycoprotein at the blood-brain barrier keeps it out of the central nervous system.

The P-glycoprotein arm has a clear mechanism and a dramatic natural experiment behind it. Dogs of herding breeds carrying an ABCB1 loss-of-function variant develop severe neurotoxicity at ivermectin exposures other dogs tolerate, because the efflux pump that normally excludes the drug from the brain is absent. The same logic applies to drugs that inhibit P-glycoprotein, including ketoconazole, itraconazole, ritonavir, verapamil, cyclosporine and amiodarone; they raise the fraction reaching the brain, so the concern is neurological rather than systemic.

Strong CYP3A4 inhibitors raise plasma ivermectin, while inducers such as rifampin and carbamazepine lower it and can undertreat the parasite. Case reports describe INR rising on warfarin after ivermectin by an unexplained mechanism. Food is worth naming alongside the drugs: a fatty meal roughly doubles absorption, which moves exposure more than most drug pairings do.

Checking a whole stack? Run it through interactions + stacks.

Ivermectin belongs to the avermectin family, a class of macrocyclic lactones discovered through a celebrated collaboration between Satoshi Omura at the Kitasato Institute in Japan and William C. Campbell at Merck in the United States during the late 1970s. Omura isolated a novel soil-dwelling actinomycete, later named Streptomyces avermitilis, from a single soil sample; Campbell's team then demonstrated that its fermentation products had extraordinary antiparasitic potency.

Chemical modification of the natural avermectins yielded ivermectin, which Merck introduced for veterinary use around 1981 and which rapidly became one of the best-selling animal-health products in the world. Human use followed, most notably against onchocerciasis (river blindness), and in 1987 Merck committed to donating the drug for as long as needed to eliminate the disease, one of the largest ongoing medical donation programs ever undertaken. In 2015 Omura and Campbell were awarded a share of the Nobel Prize in Physiology or Medicine for the discovery. Ivermectin remains a cornerstone of global efforts against several neglected tropical diseases.

Ivermectin enjoys a reputation as one of the most impactful medicines of the twentieth century, credited with transforming the outlook for hundreds of millions of people at risk of parasitic disease across the tropics. It is prized for its broad activity against roundworms and external parasites, its favorable safety margin in humans at standard antiparasitic doses, and its remarkable affordability. Its selectivity rests on a genuine biological difference: the glutamate-gated chloride channels it targets exist in invertebrate nerve and muscle but not in mammals.

The Nobel committee's recognition in 2015 underscored just how profoundly it has reduced the burden of river blindness and lymphatic filariasis. It is honest to note that widely publicized laboratory activity against viruses and cancer cells occurs only at concentrations far above those achievable with ordinary dosing, so those uses remain unproven. As an antiparasitic, however, its record is exceptional.